http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Precigen (PGEN) Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
-
Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
-
Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global Investment Conference
-
Precigen Reports Second Quarter and First Half 2021 Financial Results
-
Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th
-
Precigen Inc. (PGEN) Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
-
Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
-
Precigen to Present at the JMP Securities Life Sciences Conference
-
Precigen Reports First Quarter 2021 Financial Results
-
Precigen Inc. (PGEN) Announces Departure of Chief Financial Officer
-
Precigen Announces Departure of Chief Financial Officer
-
Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
-
Precigen Inc. (PGEN) Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
-
Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
-
Precigen Reports Fourth Quarter and Full Year 2020 Financial Results
-
Precigen to Announce Fourth Quarter and Full Year 2020 Financial Results on March 1st
-
Precigen to Participate in Guggenheim Healthcare Talks Oncology Day
-
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan Healthcare Conference
-
Precigen to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Precigen Inc. (PGEN) Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse Immunotherapy in Patients with Recurrent Respiratory Papillomatosis
-
Precigen Announces Clearance of IND to Initiate Phase I Study of PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)
-
Precigen Provides Latest Clinical Developments at Virtual R&D Update Event
-
Precigen to Host R&D Update Virtual Event on December 15th to Share Latest Clinical Developments
-
Precigen Presents New Data Supporting the Safety, Clinical Activity, Expansion and Persistence of PRGN-3006 UltraCAR-T® at the 62nd ASH Annual Meeting and Exposition
-
Lt. General (Ret.) Thomas Bostick Appointed to CSX Corp. Board of Directors
-
Precigen to Present at H.C. Wainwright 22nd Annual Global Investment Conference
-
Precigen Inc. (PGEN) Reports First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse Immunotherapy to Treat HPV-associated Cancers
-
Precigen Announces First Patient Dosed in Phase I/II Study of First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-associated Cancers
-
Precigen Reports Second Quarter and First Half 2020 Financial Results
-
Precigen, Inc. (PGEN) Reports Phase 1b Study of AG019 ActoBiotics Met Primary Endpoint Assessing Safety and Tolerability
-
Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
-
Precigen, Inc. (PGEN) Provides Six-month Follow-up Data from Phase I Study of INXN-4001
-
Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure
-
Precigen to Announce Second Quarter and First Half 2020 Financial Results on August 10th
-
Precigen, Inc. (PGEN) Announces Preclinical Data for PRGN-3005 UltraCAR-T Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T
-
Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T
-
Precigen to Participate in Upcoming JMP Securities Hematology and Oncology Forum
-
Notice: Precigen Announces Date and Location Change for its 2020 Annual Meeting of Shareholders
-
Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™ at the AACR Virtual Annual Meeting II in June 2020
-
Precigen Reports First Quarter 2020 Financial Results
-
Precigen to Announce First Quarter 2020 Financial Results on May 6th
-
Precigen, Inc. (PGEN) Reports IND Approval to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse Immunotherapy
-
Precigen Announces Clearance of IND to Initiate Phase I/II Study for First-in-Class PRGN-2009 AdenoVerse™ Immunotherapy to Treat HPV-positive (HPV+) Solid Tumors
-
Precigen Reports Fourth Quarter and Year End 2019 Financial Results
-
Precigen to Announce Fourth Quarter and Full Year 2019 Financial Results on March 2nd
-
Precigen Completes Series Of Transactions To Solidify Healthcare Focus

